Your industry news - first
Solution offers long-term surface protection against harmful bacteria and enveloped virus
Bioarmor tells us that in addition to its UK laboratory certification of 99.9% efficacy against Escherichia coli, Staphylococcus aureus and MRSA - Bioarmor-nano has now been independently laboratory tested to be effective (on non-porous substrates) against phi6 - an enveloped virus with a similar structure to Coronavirus* and Influenza A viruses.
The testing was carried out to a modified version of ISO 21702.
In a controlled laboratory environment, a non-porous substrate treated with Bioarmor-nano demonstrated a reduction of up to 95% of the phi6 enveloped virus after contact with it for 24 hours.
The tests were conducted by an independent UK laboratory using phi6 enveloped virus. Test conditions were based on ISO 21702 on surfaces protected by Bioarmor-nano products only.
"There is a worldwide shortage of laboratories with the protocols required to test on actual Coronavirus, so as an interim measure we have tested on the phi6 virus,” explains John Shaw, Bioarmor Europe director. “We are currently in the process of negotiating with several high protocol level labs and plan to extend our testing to a mammalian Coronavirus (human or similar) as soon as this becomes possible."
*SARS-CoV-2 is the virus that causes Covid-19 and is a member of the Coronavirus family of viruses.
Bioarmor’s product claims are based on protection to surfaces against microbes and now viruses; its products do not offer protection to the user or others against bacteria or viruses.
See the explanation video in animation at:
14th January 2021